Document:

EX-10.1

 EXHIBIT 10.1 

CINEMARK HOLDINGS, INC. 

SECOND AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR 

COMPENSATION POLICY 

Effective as of June 4, 2015 
  

	 Introduction: 
	In order to advance the interests of Cinemark Holdings, Inc. (the “Company”) and its stockholders by aligning the interests of the Company and its stockholders with Non-Employee Directors and enhancing the ability of the Company
and its Subsidiaries to attract and retain qualified Non-Employee Directors, the Company has adopted this Non-Employee Director Compensation Policy (this “Policy”), by which Non-Employee Directors are compensated for their
service to the Company. 

  

	 Eligibility: 
	Only those members of the Company’s board of directors (the “Board”) who constitute Non-Employee Directors are eligible to receive compensation under this Policy. For purposes of this Policy, “Non-Employee
Director” means any member of the Board of Directors of the Company (the “Board”) who (i) is not an employee of the Company or any of its Subsidiaries; and (ii) is not an employee of any the Company’s
stockholders with contractual rights to nominate directors (a “Significant Stockholder”). Directors who are employees of the Company, any of its Subsidiaries, or any of its Significant Stockholders are not entitled to
additional compensation on account of such director’s service on the Board. In addition, no additional compensation shall be paid to any member of the Board who serves as a director of any subsidiary of the Company. 

 

	 Cash Compensation: 
	Each Non-Employee Director shall be entitled to receive the following annual compensation (as applicable to such Non-Employee Director) in connection with the service of such Non-Employee Director as a member of the Board: 

 

	 	(a)	A base director retainer of $60,000; 

  

	 	(b)	An additional retainer of $25,000 if such Non-Employee Director serves as the Lead Director; 

  

	 	(c)	An additional retainer of $20,000 if such Non-Employee Director serves as the chairman of the Audit Committee of the Board (the “Audit Committee”); 

 

	 	(d)	An additional retainer of $10,000 if such Non-Employee Director serves as a member of the Audit Committee, other than the chairman of the Audit Committee; 

	 	(e)	An additional retainer of $10,000 if such Non-Employee Director serves as the chairman of the Compensation Committee of the Board (the “Compensation Committee”); 

 

	 	(f)	An additional retainer of $5,000 if such Non-Employee Director serves as a member of the Compensation Committee, other than the chairman of the Compensation Committee; 

 

	 	(g)	An additional retainer of $10,000 if such Non-Employee Director serves as the chairman of the Nominating and Corporate Governance Committee of the Board (the “Governance Committee”); 

 

	 	(h)	An additional retainer of $5,000 if such Non-Employee Director serves as a member of the Governance Committee; 

  

	 	(i)	An additional retainer of $10,000 if such Non-Employee Director serves as the chairman of the Strategic Planning Committee of the Board; 

 

	 	(j)	An additional retainer of $5,000 if such Non-Employee Director serves as a member of the Strategic Planning Committee; 

  

	 	(k)	An additional retainer of $10,000 if such Non-Employee Director serves as the chairman of the New Ventures Committee of the Board; and 

 

	 	(l)	An additional retainer of $5,000 if such Non-Employee Director serves as a member of the New Ventures Committee. 

  

	 Cash Payment: 
	Each Non-Employee Director shall be paid the amount of cash retainer applicable to such Non-Employee Director in four (4) equal quarterly payments to be made on the fifth (5th) business day
following the end of each fiscal quarter of the Company during which such Non-Employee Director has continuously served as a member of the Board (or applicable committee of the Board), or as soon thereafter as is administratively possible.
Notwithstanding anything in this Policy to the contrary, in the event a Non-Employee Director assumes or vacates a position on the Board or one of its committees during a quarter, such Non-Employee Director shall be entitled to a prorated portion of
the cash compensation for such position for that quarter based on the percentage of days in that quarter during which such Non-Employee Director served in the position for which the cash retainer is payable under this Policy. 

 

	 Expense Reimbursement: 
	 All Non-Employee Directors shall be entitled to reimbursement from the Company for their reasonable travel (including airfare and ground transportation), lodging and meal expenses incident
to attending meetings of the Board or committees thereof or in connection with other Board related business. The Company shall also reimburse directors for attendance at director continuing education programs that

  
 - 2 - 

	 	 
are relevant to their service on the Board and which attendance is pre-approved by the chairman of the Nominating and Corporate Governance Committee or chairman of the Board. The Company shall
make reimbursement to a Non-Employee Director within a reasonable amount of time following submission by the Non-Employee Director of reasonable written substantiation for the expenses. 

 

	 Restricted Shares: 
	Promptly following the initial election of a Non-Employee Director to the Board, or promptly following a Board member meeting the criteria of a Non-Employee Director, such Non-Employee Director shall receive a grant of Restricted Shares of the
Company’s Common Stock valued at $110,000 (the “Initial Award”) and thereafter, promptly following the anniversary of the date of election to the Board a continuing Non-Employee Director shall receive a grant of
Restricted Shares of the Company’s Common Stock valued at $110,000 (the “Annual Award”) on June 15 of every year. The valuation date of the Restricted Shares will be the date of grant of such Restricted Shares. The
number of Restricted Shares to be issued will be determined by dividing $110,000 by the Fair Market Value of a share of Common Stock on the valuation date. The Initial Award shall vest on a date determined by the Board and each Annual Award shall
vest on the first anniversary of the date of the grant, subject to the Non-Employee Director’s continued service to the Company through the vesting dates. All grants of Restricted Shares shall be made pursuant to the Company’s Amended and
Restated 2006 Long Term Incentive Plan (the “Amended and Restated Plan”). Under the Amended and Restated Plan, grants of Restricted Shares are governed by individual Restricted Share Award Agreements between the Company and a
Participant. The descriptions of these grants set forth above are qualified in their entirety by reference to the Amended and Restated Plan and the applicable Restricted Share Award Agreement issued thereunder. 

 

	 Annual Review: 
	 This Policy shall be reviewed annually by the Compensation Committee and modified as necessary to ensure its terms remain consistent with the stated interests of the Company and its
stockholders. The Compensation Committee shall have the power to construe this Policy to determine all questions arising thereunder, and to adopt and amend such rules and regulations for the administration of this Policy as it may deem desirable.
The Compensation Committee shall determine the members of the Board who qualify as Non-Employee Directors and are eligible to receive compensation under the terms of this Policy. Any decisions of the Compensation Committee in the administration of
this Policy shall be final and conclusive. The Compensation Committee may authorize one or more of its members or any officer of the Company to execute and deliver documents on its behalf. No member of the Compensation Committee shall be liable for

  
 - 3 - 

	 	 
anything done or omitted to be done by such member or by any other member of the Board or the Compensation Committee in connection with this Policy, except for such member’s own willful
misconduct or gross negligence (unless the Company’s Certificate of Incorporation or Bylaws, or any indemnification agreement between the Company and such person, in each case in accordance with applicable law, provides otherwise). The
Compensation Committee shall have the power to engage outside consultants, auditors or other professional help to assist in the fulfillment of the duties of the Compensation Committee under this Policy at the Company’s expense.

  

	 Capitalized Terms: 
	Capitalized terms used not defined in this Policy have the meanings ascribed to them in the Amended and Restated Plan. 

  
 - 4 - 

 IN WITNESS WHEREOF, upon authorization of the Compensation Committee of the Board, the
undersigned has caused this Cinemark Holdings, Inc. Second Amended and Restated Non-Employee Director Compensation Policy, to be executed effective on the 4th day of June, 2015. 

 

			
	CINEMARK HOLDINGS, INC.
		
	By:	 	/s/ Michael D. Cavalier
	Name:	 	Michael D. Cavalier
	Title:	 	Executive VP-General Counsel and SecretaryExhibit 10.1

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

SECOND
AMENDMENT

 

TO
THE LICENSE, MARKETING AND DEVELOPMENT AGREEMENT

 

This
Second Amendment (“Second Amendment”) to the License,
Marketing and Development Agreement dated November
14, 2013 (the “Original Agreement”) is effective as of April 30, 2015 (the “Second Amendment
Effective Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular
Therapeutics (“CCT”), and Alliqua BioMedical, Inc., a Delaware corporation (“Alliqua”). Alliqua
and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.

 

WHEREAS Alliqua and CCT entered into the
Original Agreement and entered into a certain First Amendment to the Original Agreement (the Original Agreement, as amended thereby,
the “Agreement”).

 

WHEREAS both Parties now wish to amend
the terms of the Agreement as further described in this Second Amendment;

 

NOW and THEREFORE the Parties hereby
agrees as follows:

 

All capitalized terms used in this Second
Amendment shall have the meaning ascribed to them in the Agreement, except as otherwise expressly stated herein. As of the Second
Amendment Effective Date, the Agreement is amended as follows:

 

		1.	Article 1 (Definitions) is amended by adding the following new definitions in alphabetical order:

 

“CTMs” means
allogeneic connective tissue matrix derived from the chorionic plate of the human placenta as produced according to the CCT Technology.

 

“Tissue Matrix”
means each of ECMs and CTMs, and “Tissue Matrixes” means ECMs and CTMs.

 

		2.	The defined term “Competing Product” in Article 1 (Definitions) of the Agreement shall
be deleted and replaced in its entirety with the following definition: 

 

“Competing Product”
means, with respect to Biovance and ECMs, any advanced biologic wound care biological skin substitute product [****]
in the Field, other than a Licensed Product. With respect to CTMs, “Competing Product” means any advanced biologic
wound care biological integumental tissue replacement or supplementation product [****]
in the Field, other than a Licensed Product.

 

		3.	The defined term “Field” in Article 1 (Definitions) of the Agreement shall be deleted
and replaced in its entirety with the following definition: 

 

“Field” means
acute and chronic non-healing wounds: pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunnel/undermined
wounds, surgical wounds (donor sites/grafts, dehiscence), trauma wounds (abrasions, lacerations, second degree burns, and skin
tears), and draining wounds. With respect to Biovance and CTMs, “Field” also means podiatric and orthopedic applications
for homologous uses that include the repair of damaged or inadequate tissue to provide functional support of tendon, nerve, muscle
and bone.

 

    	 

    	 

    

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

		4.	The defined term “Launch Year” in Article 1 (Definitions) of the Agreement shall be
deleted and replaced in its entirety with the following definition:

 

“Launch Year”
means, for Biovance, (i) with respect to the first Launch Year, the 12-month period beginning on the first day of the calendar
month immediately preceding the first anniversary of the First Commercial Sale of Biovance and (ii) with respect to any subsequent
Launch Year, the 12-month period beginning on the first day of the relevant anniversary of the first Launch Year. With respect
to the Tissue Matrixes, “Launch Year” means (i) with respect to the first Launch Year, the 12-month period beginning
on the first day of the calendar month immediately preceding the first anniversary of the First Commercial Sale of a Tissue Matrix,
and (ii) with respect to any subsequent Launch Year, the 12-month period beginning on the first day of the relevant anniversary
of the first Launch Year. Solely by way of example, if the First Commercial Sale occurs on April 15, 2014, the first Launch Year
shall commence on April 1, 2014 and each subsequent Launch Year shall commence on April 1 of each subsequent year.

 

		5.	The defined term “Licensed Product” in Article 1 (Definitions) of the Agreement shall
be deleted and replaced in its entirety with the following definition: 

 

“Licensed Product”
means each of Biovance, ECMs, CTMs and any and all Improvements thereof; and “Licensed Products” means, collectively,
Biovance, ECMs and CTMs, and any and all Improvements of each of them.

 

		6.	The defined term “Market Condition Change” in Article 1 (Definitions) of the Agreement
shall be deleted and replaced in its entirety with the following definition: 

 

“Market Condition Change”
means, (i) for Biovance, at any time during the [****] of this
Agreement, and (ii) for a Tissue Matrix, at any time during the [****]
after the First Commercial Sale thereof, factors outside the reasonable control of Alliqua, including supply shortages or outages,
changes in any Governmental Authority or Regulatory Authority regulation or reimbursement rate, and/or any Regulatory Authority
action, which would adversely affect the Commercialization of such Licensed Product in any material respect.

 

		7.	The defined term “Regulatory Clearances and/or Approvals” in Article 1 (Definitions)
of the Agreement shall be deleted and replaced in its entirety with the following definition:

 

“Regulatory Clearances
and/or Approvals” means all approvals necessary for the commercial sale of a Licensed Product for any indication in a
given country or regulatory jurisdiction in the Territory, which shall include satisfaction of all applicable regulatory and notification
requirements, and shall be deemed to include any stockpiling by any Governmental Authority for civilian or military use, but which
shall exclude any pricing and reimbursement approvals. With respect to any CTMs, Regulatory Clearances and/or Approvals shall be
deemed to have been obtained if (i) such Licensed Product conforms in all material respects to the product description set forth
in the FDA letter of October 15, 2004 to Dr. Jeffrey Miller concerning CCT’s request for designation submitted to the FDA
on August 19, 2004, or (ii) in the reasonable determination of CCT, otherwise meets the criteria contained in 21 CFR 1271.10(a)
for regulation under 21 CFR 1271 and Section 361 of the Public Health Services Act.

 

    	2

    	 

    

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

		8.	The defined term “Supply Agreement” in Article 1 (Definitions) of the Agreement shall
be deleted and replaced in its entirety with the following definition:

 

“Supply
Agreement” means, as context requires: (i) that certain Supply Agreement entered into by the Parties dated November 14,
2013 (as amended by the Parties from time to time); or (ii) that certain Supply Agreement entered into by the Parties dated April
10, 2014 (as amended by the Parties from time to time); or (iii) any other agreement entered into between the Parties for the supply
by CCT of a Licensed Product to Alliqua.

 

		9.	Section 2.1(a) of Article 2 (Licenses) of the Agreement is amended by inserting the following as
the last sentence of such section:

 

“The license grant set
forth in this Section 2.1(a) is also subject to CCT’s right to Develop CTMs pursuant to Section 4.1 below.”

 

		10.	Article 2 (License) of the Agreement is amended by adding the following new Section 2.7 after Section
2.6 thereof.

 

2.7 Manufacture and
Supply of CTMs. Prior to anticipated First Commercial Sale of CTMs, the Parties shall enter into a supply agreement with
respect to CTMs on substantially the same terms as the Supply Agreement for ECMs, except that the purchase price for CTMs
shall be negotiated by the Parties in good faith and shall be set forth in such supply agreement. Upon the Parties’
full execution of such supply agreement, it shall be deemed a “Supply Agreement” hereunder.

 

		11.	Section 4.1 of Article 4 (Development) of the Agreement is amended by inserting the following immediately
after the second sentence of such section:

 

“In further addition,
Alliqua shall submit a Joint Development Plan for CTMs (similar in nature to the Joint Development Plans submitted for Biovance
and ECMs) to the JSC no later than ninety (90) days prior to anticipated First Commercial Sale of CTMs, such Joint Development
Plan to be discussed in good faith between the Parties prior to JSC submission, it being understood and agreed that CCT shall have
the right to continue to Develop CTMs. For clarity, Alliqua’s obligation to use Commercially Reasonable Best Efforts to undertake
the Development activities for CTMs (and conduct the related clinical studies and perform all such related activities) set forth
in, and in accordance with the applicable Joint Development Plan, is subject to CCT’s right to continue to Develop CTMs.”

 

		12.	Section 6.2 of Article 6 (Commercialization) of the Agreement is amended by inserting the following
immediately after the third sentence of such section:

 

“In
further addition, Alliqua shall submit an initial Commercialization Plan for CTMs to the JSC
no later than ninety (90) days prior to the First Commercial Sale of CTMs in each relevant jurisdiction within the Territory.”

 

		13.	Schedule 7.2 (Milestone Payments) of the Agreement shall be deleted and replaced in its entirety
with Schedule 7.2 attached to this Second Amendment.

 

    	3

    	 

    

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

		14.	Article 14 (Miscellaneous) of the Agreement is amended to add the following Section 14.13:

 

“14.13 Tissue Matrixes.
The Parties agree that for purposes of Article 7 (Compensation) and Section 12.2(b) of Section 12 (Term and Termination) the Tissue
Matrixes shall be treated on an aggregate basis as if a single Licensed Product, but for the avoidance of doubt, shall not be treated
on an aggregate basis for purposes of Sections 12.2(c), 12.5 or 12.6 of Article 12 (Term and Termination). The Parties further
agree that (i) there shall be only a single aggregated Annual License Fee for any and all Tissue Matrixes, (ii) the Milestone Events
listed in (8) – (11) of Schedule 7.2 hereto shall be calculated based on the aggregate Net Sales of any and all Tissue
Matrixes, (ii) there shall only be a single Milestone Payment for all Tissue Matrixes for each Milestone Event listed in (5) –(7)
of Schedule 7.2 hereto, and (iv) any royalty payment required under Section 7.3 with respect to any and all Tissue Matrixes
shall be determined on an aggregate basis.”

 

		15.	Section 3.1(c)(ii)(1) (Governance), Schedules 7.1(a) (Annual License Fees), 7.1(b) (Annual License
Fees and Base Purchase Price Examples), and 7.3(a) (Royalties) of the Agreement are amended by replacing any references therein
to “ECMs” or “ECM” with “Tissue Matrixes.”

 

Performance under
all other terms of the Agreement: Except as expressly amended hereby, the Agreement shall remain in full force and effect as
presently written, and the rights, duties, liabilities and obligations of the Parties thereto, as presently constituted, will continue
in full effect. This Second Amendment is incorporated and made a part of the Agreement between the Parties. This Second Amendment,
together with the Agreement, constitutes the entire agreement between the Parties with respect to the subject matter contained
therein, and together, supersede and replace any prior and/or contemporaneous discussions, understandings, representations or agreements,
whether written or oral, with respect to the subject matter thereof.

 

Counterparts:
This Second Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original but all of which
together shall constitute the same legal instrument. Facsimile or PDF execution and delivery of this Second Amendment by any Party
shall constitute a legal, valid and binding execution and delivery of this Second Amendment by such Party. The Parties to this
document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which
the original signature may have been used. The Parties agree they will have no rights to challenge the use or authenticity of this
document based solely on the absence of an original signature.

 

[SIGNATURE PAGE ON NEXT PAGE]

 

    	4

    	 

    

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

IN WITNESS WHEREOF,
each of the Parties has caused this Second Amendment to be executed, as of the Second Amendment Effective Date, by its duly authorized
officer or representative.

 

	ANTHROGENESIS CORPORATION	 	ALLIQUA BIOMEDICAL, INC.
	 	 	 	 	 
	By:	/s/ Perry Karsen	 	By:	/s/ Lori Toner
	 	 	 
	Name: Perry Karsen	 	Name: Lori Toner
	 	 	 
	Title: Chief Executive Officer	 	Title: Chief Marketing Officer

 

    	5

    	 

    

 

THE
COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL
PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED
IN THIS EXHIBIT WITH “*****”.

 

Schedule 7.2

 

Milestone Payments

 

	 	 	Milestone Event for Biovance 	 	Milestone Payment
	1	 	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	 	[****]
	2	 	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	 	[****]
	3	 	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	 	[****]
	4	 	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	 	[****]

 

	 	 	Milestone Event for any and all Tissue Matrixes	 	Milestone Payment
	5	 	The earlier to occur of: (1) 510(k) or other Regulatory Clearance and/or Approval of ECM [****]; or (2) First Commercial Sale of CTMs [****]	 	[****]
	6	 	The earlier to occur of: (1) 510(k) or other Regulatory Clearance and/or Approval of ECM [****]; or (2) First Commercial Sale of CTMs [****]	 	[****]
	7	 	The earlier to occur of: (1) 510(k) or other Regulatory Clearance and/or Approval of ECM [****]; or (2) First Commercial Sale of CTMs [****]	 	[****]
	8	 	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	 	[****]
	9	 	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	 	[****]
	10	 	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	 	[****]
	11	 	At such time as aggregate annual Net Sales for any rolling twelve month period equal or exceed [****]	 	[****]

 

    	6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]